In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients
BACKGROUND: Persistent immune activation and inflammation are lying behind HIV-infection even in the setting of ART mediated viral suppression. The purpose of this study is to define the in vivo effect of two first-line ART regimens on certain inflammatory mediators in male HIV patients.
METHODS: Male, naive, HIV-infected volunteers were assigned either to tenofovir-DF/emtricitabine/efavirenz (Group_T) or abacavir/lamivudine/efavirenz (Group_A). Platelet Activating Factor (PAF) levels and metabolic enzymes together with HIV-implicated cytokines (IL-1beta, IL-6, IL-8, IL-10, IL-12p70, TNFa) and VEGF were determined for a 12-month period. Differences within each group were determined by non-parametric Friedman and Wilcoxon test, while the differences between the groups were checked by ANOVA repeated measures.
RESULTS: Both ART regimens present pronounced effect on inflammatory mediators, resulting in decreased PAF levels and Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity for tenofovir-containing regimen and same as baseline PAF levels with a peak though at the 3rd month as well as elevated Lp-PLA2 activity for abacavir-containing regimen.
CONCLUSIONS: Studies regarding the effect of first-line ART regimens on inflammation may be beneficial in preventing chronic morbidities during HIV-treatment. From this point of view, the present study suggests an anti-inflammatory effect of tenofovir-containing ART, while the temporary increase of PAF levels in abacavir-containing ART may be the link between the reported cardiovascular risk and abacavir administration.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Lipids in health and disease - 13(2014) vom: 29. Mai, Seite 90 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Papakonstantinou, Vasiliki D [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.11.2014 Date Revised 04.11.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/1476-511X-13-90 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM238758230 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM238758230 | ||
| 003 | DE-627 | ||
| 005 | 20231224114459.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/1476-511X-13-90 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0795.xml |
| 035 | |a (DE-627)NLM238758230 | ||
| 035 | |a (NLM)24884881 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Papakonstantinou, Vasiliki D |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.11.2014 | ||
| 500 | |a Date Revised 04.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Persistent immune activation and inflammation are lying behind HIV-infection even in the setting of ART mediated viral suppression. The purpose of this study is to define the in vivo effect of two first-line ART regimens on certain inflammatory mediators in male HIV patients | ||
| 520 | |a METHODS: Male, naive, HIV-infected volunteers were assigned either to tenofovir-DF/emtricitabine/efavirenz (Group_T) or abacavir/lamivudine/efavirenz (Group_A). Platelet Activating Factor (PAF) levels and metabolic enzymes together with HIV-implicated cytokines (IL-1beta, IL-6, IL-8, IL-10, IL-12p70, TNFa) and VEGF were determined for a 12-month period. Differences within each group were determined by non-parametric Friedman and Wilcoxon test, while the differences between the groups were checked by ANOVA repeated measures | ||
| 520 | |a RESULTS: Both ART regimens present pronounced effect on inflammatory mediators, resulting in decreased PAF levels and Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity for tenofovir-containing regimen and same as baseline PAF levels with a peak though at the 3rd month as well as elevated Lp-PLA2 activity for abacavir-containing regimen | ||
| 520 | |a CONCLUSIONS: Studies regarding the effect of first-line ART regimens on inflammation may be beneficial in preventing chronic morbidities during HIV-treatment. From this point of view, the present study suggests an anti-inflammatory effect of tenofovir-containing ART, while the temporary increase of PAF levels in abacavir-containing ART may be the link between the reported cardiovascular risk and abacavir administration | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Alkynes |2 NLM | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Benzoxazines |2 NLM | |
| 650 | 7 | |a Cyclopropanes |2 NLM | |
| 650 | 7 | |a Interleukin-6 |2 NLM | |
| 650 | 7 | |a Interleukin-8 |2 NLM | |
| 650 | 7 | |a Organophosphonates |2 NLM | |
| 650 | 7 | |a Platelet Activating Factor |2 NLM | |
| 650 | 7 | |a Tumor Necrosis Factor-alpha |2 NLM | |
| 650 | 7 | |a Interleukin-10 |2 NLM | |
| 650 | 7 | |a 130068-27-8 |2 NLM | |
| 650 | 7 | |a Lamivudine |2 NLM | |
| 650 | 7 | |a 2T8Q726O95 |2 NLM | |
| 650 | 7 | |a Tenofovir |2 NLM | |
| 650 | 7 | |a 99YXE507IL |2 NLM | |
| 650 | 7 | |a Adenine |2 NLM | |
| 650 | 7 | |a JAC85A2161 |2 NLM | |
| 650 | 7 | |a efavirenz |2 NLM | |
| 650 | 7 | |a JE6H2O27P8 |2 NLM | |
| 700 | 1 | |a Chini, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Mangafas, Nikos |e verfasserin |4 aut | |
| 700 | 1 | |a Stamatakis, George M |e verfasserin |4 aut | |
| 700 | 1 | |a Tsogas, Nickolaos |e verfasserin |4 aut | |
| 700 | 1 | |a Tsoupras, Alexandros B |e verfasserin |4 aut | |
| 700 | 1 | |a Psarra, Katherina |e verfasserin |4 aut | |
| 700 | 1 | |a Fragopoulou, Elizabeth |e verfasserin |4 aut | |
| 700 | 1 | |a Antonopoulou, Smaragdi |e verfasserin |4 aut | |
| 700 | 1 | |a Gargalianos, Panagiotis |e verfasserin |4 aut | |
| 700 | 1 | |a Demopoulos, Constantinos A |e verfasserin |4 aut | |
| 700 | 1 | |a Lazanas, Marios-C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lipids in health and disease |d 2002 |g 13(2014) vom: 29. Mai, Seite 90 |w (DE-627)NLM123930782 |x 1476-511X |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2014 |g day:29 |g month:05 |g pages:90 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/1476-511X-13-90 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2014 |b 29 |c 05 |h 90 | ||